Occurrence of Psoriatic Arthritis during Interferon Beta 1a Treatment for Multiple Sclerosis.
Interferon beta (IFN- β ) is the first line therapy of relapsing-remitting multiple sclerosis. IFN- β is a cytokine that can contribute to the development of systemic autoimmune disease including psoriasis. The development or the exacerbation of psoriasis during IFN- β treatment has been previously observed. We report the occurrence of arthritis and dactylitis in a multiple sclerosis patient with preexisting psoriasis diagnosed as a psoriatic arthritis. The IL-23/Th17 pathway is involved in psoriasis and psoriatic arthritis and it has been suggested that IFN- β therapy in patients with Th17-mediated disease may be detrimental. Together with previous similar reports, our case suggests that IFN- β should certainly be used with caution in patients with concomitant systemic autoimmune disease with IL-23/Th17 involvement.
Clinical Investigation Center Biotherapy INSERM CIC-1431, FHU INCREASE, University Hospital Besançon, Place Saint Jacques, 25000 Besançon, France ; Department of Rheumatology, University Hospital Besançon, 25000 Besançon, France ; Department of Therapeutics, University of Franche-Comté, 25000 Besançon, France ; Pathogens and Inflammation Laboratory, University of Franche-Comté, UPRES EA 4266, SFR FED 4234, 25000 Besançon, France.
Eric
E
Toussirot
Department of Neurology, University Hospital Besançon, 25000 Besançon, France.
Matthieu
M
Béreau
Department of Rheumatology, Belfort-Montbéliard Hospital, 90000 Belfort, France.
Marie
M
Bossert
Department of Neurology, Belfort-Montbéliard Hospital, 90000 Belfort, France.
Imad
I
Malkoun
Department of Rheumatology, Belfort-Montbéliard Hospital, 90000 Belfort, France.
Anne
A
Lohse